Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CFRX

ContraFect (CFRX) Stock Price, News & Analysis

ContraFect logo

About ContraFect Stock (NASDAQ:CFRX)

Advanced Chart

Key Stats

Today's Range
$0.05
$0.06
50-Day Range
$0.05
$0.07
52-Week Range
$0.04
$13.02
Volume
910,216 shs
Average Volume
1.39 million shs
Market Capitalization
$535 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive CFRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ContraFect and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CFRX Stock News Headlines

22R.BE,0P0001D9RF,0 (22R.BE)
RegenETP, Inc. (RGTPQ)
Why Trump’s “Smart Dollar” could rewrite the rules
MUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's latest plans for the dollar – and they're so bold that one central bank chair says we haven't seen anything like it in almost a century. Our Wall Street insider says it's the start of a once-in-a-lifetime investing opportunity, IF you act now.tc pixel
ContraFect Corp CFRXQ
ContraFect Corp CFRX
ContraFect: Q3 Earnings Snapshot
Why Is ContraFect (CFRX) Stock Up 23% Today?
See More Headlines

CFRX Stock Analysis - Frequently Asked Questions

ContraFect Co. (NASDAQ:CFRX) issued its earnings results on Monday, November, 15th. The biotechnology company reported ($10.40) earnings per share for the quarter, beating the consensus estimate of ($22.64) by $12.24.

ContraFect shares reverse split on Tuesday, February 14th 2023.The 1-80 reverse split was announced on Tuesday, February 14th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that ContraFect investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Meta Platforms (META), Tonix Pharmaceuticals (TNXP), Novavax (NVAX), VBI Vaccines (VBIV) and Cidara Therapeutics (CDTX).

Company Calendar

Last Earnings
11/15/2021
Today
9/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CFRX
CIK
1478069
Fax
N/A
Employees
23
Year Founded
2008

Profitability

EPS (Trailing Twelve Months)
($19.27)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$65.15 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-138.70%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.53
Quick Ratio
0.53

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($19.92) per share
Price / Book
0.00

Miscellaneous

Outstanding Shares
10,700,000
Free Float
10,639,000
Market Cap
$535 thousand
Optionable
Not Optionable
Beta
0.29

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:CFRX) was last updated on 9/11/2025 by MarketBeat.com Staff
From Our Partners